Emisphere Reports Positive Results of Oral B12 Animal Studies
Posted on: Friday, 8 February 2008, 09:00 CST
Emisphere Technologies has said that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen technology was 15-30 times greater than with the same dose of oral vitamin B12 administered alone.
Emisphere's eligen technology is the basis of the company's unique and improved delivery of therapeutic molecules and pharmaceutical compounds.
Michael Novinski, president and CEO of Emisphere, said: "This data demonstrates an exciting potential commercial avenue for our technology that can have a positive impact on the lives of many patients and Emisphere."
Source: Datamonitor
Related Articles
- Emisphere Technologies Presentation at the Rodman and Renshaw Techvest Annual Healthcare Conference to Be Webcast
- Emisphere to Commence Phase II Oral Insulin Clinical Trial
- Emisphere Technologies Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference to Be Webcast
- Emisphere Technologies, Inc. Receives NASDAQ Letter Addressing Need to Add Director
- Emisphere Technologies Presentation at the Merriman Curhan Ford & Co. 2nd Annual Investor Summit to Be Webcast
- Emisphere Technologies Completes Dosing in Heparin Clinical Trial
- Emisphere Technologies Presentation at the Oppenheimer Diabetes Conference to Be Webcast
- Emisphere Technologies Announces 2005 Second Quarter Results
- Emisphere Announces Sale of Connecticut Facility
- Emisphere Announces First Milestone in Roche Collaboration
Rating: 2.6 / 5 (15 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds